Deltapine cotton announced the release of three new Bollgard® 3 XtendFlex cotton varieties as part of the brand’s Class of 19 lineup during the annual New Product Evaluator (NPE) Summit held today in Phoenix, Arizona.
“The Deltapine Class of 19 features a diverse group of varieties that focus on bringing regional-fit products to specific areas where farmers have expressed need,” said Keylon Gholston, Deltapine Cotton Product Manager. “We are excited about how well these new cotton varieties fit within our broader portfolio and fill needs within the broader Deltapine variety lineup.”
The Deltapine Class of 19 includes three varieties ideal for the southwestern market and a variety developed for the Mid-South and Southeast. The four new varieties feature XtendFlex technology as part of the Roundup Ready Xtend Crop System, making them tolerant to three modes of action for flexible and effective weed management.
The Class of 19 varieties for Southwest geographies are:
- DP 1948 B3XF
- DP 1908 B3XF
- DP 1909 XF
The Class of 19 variety for Mid-South/Southeast geographies is:
- DP 1916 B3XF
DP 1948 B3XF is a mid-full maturity variety showing good yield potential, especially in the tough growing conditions of Texas. The new DP 1948 B3XF is similar to DP 1646 B2XF, showing the ability to elevate performance in low-yield environments. This variety, which offers Bollgard 3 technology, for added protection against cotton bollworms, it is well-adapted to the markets of South Texas, Rolling Plains and Southern High Plains.
DP 1908 B3XF and DP 1909 XF are both products from the Deltapine West Texas breeding and testing programs with very early-to-early maturity. Both varieties have shown good early vigor and are smooth-leaf varieties with resistance to bacterial blight. Both varieties offer excellent fiber quality and are adapted for the Northern High Plains and Panhandle markets of Texas, as well as Oklahoma and Kansas.
DP 1916 B3XF is an early-maturity variety that demonstrated good fiber quality and outstanding yield potential in 2018 NPE grower evaluations. Positioned for the northern areas of the Mid-South, the Carolinas and Virginia, this variety compares well to DP 1614 B2XF, but offers better early vigor and stand establishment. It is comparable in yield potential to DP 1725 B2XF and offers Bollgard 3 protection.
Each NPE variety candidate must bring a combination of improved yield, fiber quality and agronomics, including trait stack, to the market before it can be commercially named, and the Class of 19 is no exception. All four new varieties were evaluated by Deltapine NPE growers, who grew them in module, or larger, sized plots under their own management styles and growing conditions.
“The commitment we made to NPE growers when we started this program in 2008 was that we would only commercialize a variety if it performed as well as, or better than, current Deltapine varieties on the market in terms of yield, fiber quality, trait technology or disease package,” said Gholston. “Over the past decade, I think we’ve done a great job of living up to that commitment with our new varieties.”
Since it began in 2008, the Deltapine NPE Program has become the cotton industry’s premier field evaluation program, resulting in the commercialization of some of the top-planted varieties by growing region across the Belt. For more on Deltapine cotton varieties and the NPE Program, visit www.deltapine.com. Photos, videos, agronomic tips and more can be found on Twitter® (@Deltapine) and on Facebook® at https://www.facebook.com/Deltapine.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.